• Ken Sato, Masahiko Gosho, Takaya Yamamoto, Yuji Kobayashi, Norimitsu Ishii, Tomohiko Ohashi, Yukiomi Nakade, Kiyoaki Ito, Yoshitaka Fukuzawa, and Masashi Yoneda.
• Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan. Electronic address: ken90041@aichi-med-u.ac.jp.
• Nutrition. 2015 Jul 1; 31 (7-8): 923-30.

ObjectivesVitamin E is often used in the treatment of nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH); however, the magnitude of treatment response associated with vitamin E in improving liver function and histology in NAFLD/NASH has not, to our knowledge, been quantified systematically. Thus, we conducted a meta-analysis of randomized controlled trials (RCTs) using vitamin E in the treatment of NAFLD/NASH.MethodsPubMed, Medline, and Cochrane Library Full Text Database, and Japan Medical-Literature Database (Igaku Chuo Zasshi) were searched until March 2014, and five RCTs were identified for meta-analysis.ResultsAccording to a random effect model analysis of the five studies, vitamin E significantly reduced aspartate transaminase (AST) by -19.43 U/L, alanine aminotransferase (ALT) by -28.91 U/L, alkaline phosphatase (ALP) by -10.39 U/L, steatosis by -0.54 U/L, inflammation by -0.20 U/L, and hepatocellular ballooning by -0.34 U/L compared with the control group. Vitamin E treatment with NASH adult patients showed obvious reductions in not only AST of -13.91 U/L, ALT by -22.44 U/L, steatosis of -0.67 U/L, inflammation of -0.20 U/L, but also fibrosis of -0.30 U/L compared to the control treatment.ConclusionsVitamin E significantly improved liver function and histologic changes in patients with NAFLD/NASH.Copyright © 2015 Elsevier Inc. All rights reserved.

34 keywords...

hide…